Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.

Epperla N, Pham AQ, Burnette BL, Wiseman GA, Habermann TM, Macon WR, Ansell SM, Inwards DJ, Micallef IN, Johnston PB, Markovic SN, Porrata LF, Colgan JP, Ristow KM, Nowakowski GS, Witzig TE.

Br J Haematol. 2017 Aug;178(3):427-433. doi: 10.1111/bjh.14688. Epub 2017 May 3.

PMID:
28466487
2.

Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issue.

Pham AQ, Broski SM, Habermann TM, Jevremovic D, Wiseman GA, Feldman AL, Maurer MJ, Ristow KM, Witzig TE.

Leuk Lymphoma. 2017 Oct;58(10):2342-2348. doi: 10.1080/10428194.2017.1300891. Epub 2017 Mar 14.

PMID:
28290723
3.

Clinical Presentation and Diagnostic Challenges of Thyroid Lymphoma: A Cohort Study.

Sharma A, Jasim S, Reading CC, Ristow KM, Villasboas Bisneto JC, Habermann TM, Fatourechi V, Stan M.

Thyroid. 2016 Aug;26(8):1061-7. doi: 10.1089/thy.2016.0095. Epub 2016 Jul 6.

PMID:
27256107
4.

Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution.

Kenderian SS, Habermann TM, Macon WR, Ristow KM, Ansell SM, Colgan JP, Johnston PB, Inwards DJ, Markovic SN, Micallef IN, Thompson CA, Porrata LF, Martenson JA, Witzig TE, Nowakowski GS.

Blood. 2016 Apr 21;127(16):1960-6. doi: 10.1182/blood-2015-08-665505. Epub 2016 Feb 2.

5.

Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma.

Parikh SA, Habermann TM, Chaffee KG, Call TG, Ding W, Leis JF, Macon WR, Schwager SM, Ristow KM, Porrata LF, Kay NE, Slager SL, Shanafelt TD.

Am J Hematol. 2015 Apr;90(4):334-8. doi: 10.1002/ajh.23939. Epub 2015 Jan 30.

6.

ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.

Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL.

Blood. 2014 Aug 28;124(9):1473-80. doi: 10.1182/blood-2014-04-571091. Epub 2014 Jun 3.

7.

Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma.

Smeltzer JP, Jones JM, Ziesmer SC, Grote DM, Xiu B, Ristow KM, Yang ZZ, Nowakowski GS, Feldman AL, Cerhan JR, Novak AJ, Ansell SM.

Clin Cancer Res. 2014 Jun 1;20(11):2862-72. doi: 10.1158/1078-0432.CCR-13-2367. Epub 2014 Apr 11.

8.

Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.

Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN.

Leuk Lymphoma. 2014 Dec;55(12):2728-38. doi: 10.3109/10428194.2014.893313. Epub 2014 Mar 19.

PMID:
24547705
9.

Bowel perforation in intestinal lymphoma: incidence and clinical features.

Vaidya R, Habermann TM, Donohue JH, Ristow KM, Maurer MJ, Macon WR, Colgan JP, Inwards DJ, Ansell SM, Porrata LF, Micallef IN, Johnston PB, Markovic SN, Thompson CA, Nowakowski GS, Witzig TE.

Ann Oncol. 2013 Sep;24(9):2439-43. doi: 10.1093/annonc/mdt188. Epub 2013 May 22.

10.

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma.

Porrata LF, Ristow KM, Habermann TM, Macon WR, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN.

Blood Cancer J. 2013 Apr 19;3:e110. doi: 10.1038/bcj.2013.8.

11.

Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma.

Halfdanarson TR, Rubio-Tapia A, Ristow KM, Habermann TM, Murray JA, Inwards DJ.

Clin Gastroenterol Hepatol. 2010 Dec;8(12):1042-7. doi: 10.1016/j.cgh.2010.09.007. Epub 2010 Sep 17.

12.

Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era.

Nowakowski GS, Maurer MJ, Habermann TM, Ansell SM, Macon WR, Ristow KM, Allmer C, Slager SL, Witzig TE, Cerhan JR.

J Clin Oncol. 2010 Jan 20;28(3):412-7. doi: 10.1200/JCO.2009.23.4245. Epub 2009 Dec 14.

13.

Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone.

Simpson L, Ansell SM, Colgan JP, Habermann TM, Inwards DJ, Ristow KM, Johnston PB, Markovic SN, Micallef IN, Porrata LF, Witzig TE.

Leuk Lymphoma. 2007 Jul;48(7):1332-7.

PMID:
17613762
14.

Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab.

Witzig TE, Inwards DJ, Habermann TM, Dogan A, Kurtin PJ, Gross JB Jr, Ananthamurthy A, Ristow KM, Garity JA.

Mayo Clin Proc. 2007 Jun;82(6):692-9.

PMID:
17550749
15.

Prospective study of survival outcomes in Non-Hodgkin's lymphoma patients with rheumatoid arthritis.

Mikuls TR, Endo JO, Puumala SE, Aoun PA, Black NA, O'Dell JR, Stoner JA, Boilesen EC, Bast MA, Bergman DA, Ristow KM, Ooi M, Armitage JO, Habermann TM.

J Clin Oncol. 2006 Apr 1;24(10):1597-602. Epub 2006 Mar 6.

PMID:
16520462
16.

Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.

Ghobrial IM, Habermann TM, Maurer MJ, Geyer SM, Ristow KM, Larson TS, Walker RC, Ansell SM, Macon WR, Gores GG, Stegall MD, McGregor CG.

J Clin Oncol. 2005 Oct 20;23(30):7574-82. Epub 2005 Sep 26.

PMID:
16186599
17.

Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.

Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM.

J Clin Oncol. 2005 Oct 20;23(30):7614-20. Epub 2005 Sep 26.

PMID:
16186594
18.

Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?

Ghobrial IM, Habermann TM, Macon WR, Ristow KM, Larson TS, Walker RC, Ansell SM, Gores GJ, Stegall MD, McGregor CG.

Transplantation. 2005 Jan 27;79(2):244-7.

PMID:
15665775
19.

Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era.

Ghobrial IM, Habermann TM, Ristow KM, Ansell SM, Macon W, Geyer SM, McGregor CG.

Leuk Lymphoma. 2005 Feb;46(2):191-6.

PMID:
15621801
20.

Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome.

Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, Harder B, Ristow KM, Bram RJ, Jelinek DF, Gross JA, Ansell SM.

Blood. 2004 Oct 15;104(8):2247-53. Epub 2004 Jul 13.

21.

Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.

Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE.

J Clin Oncol. 2002 Sep 15;20(18):3885-90.

PMID:
12228209

Supplemental Content

Loading ...
Support Center